ECSP17046065A - Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional) - Google Patents
Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional)Info
- Publication number
- ECSP17046065A ECSP17046065A ECIEPI201746065A ECPI201746065A ECSP17046065A EC SP17046065 A ECSP17046065 A EC SP17046065A EC IEPI201746065 A ECIEPI201746065 A EC IEPI201746065A EC PI201746065 A ECPI201746065 A EC PI201746065A EC SP17046065 A ECSP17046065 A EC SP17046065A
- Authority
- EC
- Ecuador
- Prior art keywords
- methylpropyl
- dimethylamino
- ethyl
- phenolhydrochloride
- divisional application
- Prior art date
Links
- ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se relaciona con una nueva forma cristalina de clorhidrato de (-) ( 1R, 2R ) 3 ( 3 dimetilamino 1 etil 2 metilpropil ) fenol, métodos para su preparación y uso, y composiciones farmacéuticas que la contienen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04015091A EP1612203B1 (en) | 2004-06-28 | 2004-06-28 | Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17046065A true ECSP17046065A (es) | 2018-11-30 |
Family
ID=34925507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201746065A ECSP17046065A (es) | 2004-06-28 | 2017-07-17 | Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional) |
Country Status (27)
| Country | Link |
|---|---|
| US (16) | US20070213405A1 (es) |
| EP (2) | EP1612203B1 (es) |
| JP (1) | JP4990764B2 (es) |
| KR (1) | KR101096501B1 (es) |
| CN (1) | CN1997621B (es) |
| AR (2) | AR049949A1 (es) |
| AT (2) | ATE368639T1 (es) |
| AU (1) | AU2005256512B2 (es) |
| BR (2) | BR122018014454B8 (es) |
| CA (1) | CA2572147C (es) |
| CY (2) | CY1106929T1 (es) |
| DE (2) | DE602004007905T2 (es) |
| DK (2) | DK1612203T3 (es) |
| EC (1) | ECSP17046065A (es) |
| ES (2) | ES2291780T3 (es) |
| HR (1) | HRP20110050T8 (es) |
| IL (1) | IL180373A (es) |
| MX (1) | MXPA06014741A (es) |
| NO (3) | NO338605B1 (es) |
| NZ (1) | NZ551605A (es) |
| PE (1) | PE20060372A1 (es) |
| PL (2) | PL1612203T3 (es) |
| PT (2) | PT1612203E (es) |
| RU (1) | RU2423345C2 (es) |
| SI (2) | SI1612203T1 (es) |
| WO (1) | WO2006000441A2 (es) |
| ZA (1) | ZA200700774B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| ES2291780T3 (es) * | 2004-06-28 | 2008-03-01 | Grunenthal Gmbh | Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol. |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| DE102007019417A1 (de) * | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
| HRP20170481T1 (hr) * | 2007-12-07 | 2017-05-19 | Grünenthal GmbH | Kristalne modifikacije (1r, 2r)-3-(3-dimentil amino-1-etil-2-metil-propil) fenola |
| TWI454288B (zh) | 2008-01-25 | 2014-10-01 | Gruenenthal Chemie | 藥物劑型 |
| ES2599031T3 (es) | 2008-05-09 | 2017-01-31 | Grünenthal GmbH | Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización |
| US20100272815A1 (en) * | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
| BR112012001466A2 (pt) | 2009-07-22 | 2020-08-11 | Grünenthal GmbH | forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem |
| ES2534908T3 (es) | 2009-07-22 | 2015-04-30 | Grünenthal GmbH | Forma de dosificación de liberación controlada extruida por fusión en caliente |
| US8288592B2 (en) | 2009-09-22 | 2012-10-16 | Actavis Group Ptc Ehf | Solid state forms of tapentadol salts |
| EP2566461A2 (de) | 2010-05-05 | 2013-03-13 | Ratiopharm GmbH | Festes tapentadol in nicht-kristalliner form |
| PT3650439T (pt) | 2010-07-23 | 2021-03-03 | Gruenenthal Gmbh | Sais ou cocristais de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol |
| WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
| PL2680833T3 (pl) * | 2011-03-04 | 2016-08-31 | Gruenenthal Gmbh | Pozajelitowe podawanie tapentadolu |
| EP3685827A1 (en) | 2011-03-04 | 2020-07-29 | Grünenthal GmbH | Aqueous pharmaceutical formulation of tapentadol for oral administration |
| PT3766489T (pt) | 2011-05-03 | 2022-04-07 | Gruenenthal Gmbh | Composição farmacêutica aquosa semissólida contendo tapentadol |
| BR112014002022A2 (pt) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | comprimido resistente à violação proporcionando liberação de fármaco imediata |
| JP6063462B2 (ja) | 2011-07-29 | 2017-01-18 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 即時薬剤放出を提供するタンパーレジスタント錠剤 |
| WO2013111161A2 (en) * | 2012-01-10 | 2013-08-01 | Msn Laboratories Limited | Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof |
| WO2013120466A1 (en) | 2012-02-17 | 2013-08-22 | Zentiva, K.S. | A new solid form of tapentadol and a method of its preparation |
| BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
| LT2838512T (lt) | 2012-04-18 | 2018-11-12 | Grünenthal GmbH | Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| CZ304576B6 (cs) * | 2012-07-24 | 2014-07-16 | Zentiva, K.S. | Oxalát TAPENTADOLU a způsob jeho přípravy |
| CN102924303B (zh) * | 2012-10-31 | 2013-11-20 | 合肥市新星医药化工有限公司 | 盐酸他喷他多晶型c及其制备方法和应用 |
| MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
| AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
| AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| USD730877S1 (en) | 2013-09-06 | 2015-06-02 | Plantronics, Inc. | Communications headset |
| US9599565B1 (en) * | 2013-10-02 | 2017-03-21 | Ondax, Inc. | Identification and analysis of materials and molecular structures |
| WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
| HK1224189A1 (zh) | 2013-11-26 | 2017-08-18 | Grünenthal GmbH | 通过低温研磨制备粉状药物组合物 |
| CZ307492B6 (cs) | 2014-02-04 | 2018-10-17 | Zentiva, K.S. | Pevná forma maleátu tapentadolu a způsob její přípravy |
| GB2523089A (en) * | 2014-02-12 | 2015-08-19 | Azad Pharmaceutical Ingredients Ag | Stable polymorph form B of tapentadol hydrochloride |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| JP6923447B2 (ja) | 2015-03-27 | 2021-08-18 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールの非経口投与のための安定な製剤 |
| WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
| PL3819287T3 (pl) | 2016-04-19 | 2024-03-11 | Ratiopharm Gmbh | Amorficzny fosforan tapentadolu |
| EP3515412B1 (en) | 2016-09-23 | 2025-04-23 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
| WO2018153947A1 (en) | 2017-02-23 | 2018-08-30 | Grünenthal GmbH | Tapentadol as local anesthetic |
| CA3196954A1 (en) | 2020-11-03 | 2022-05-12 | Josep Bassaganya-Riera | Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| SI9720059B (sl) * | 1996-08-14 | 2011-11-30 | Searle & Co | Kristalinična oblika 4-/5-metil-3-fenilizoksazol-4-il/benzensulfonamida |
| CA2426393C (en) * | 2000-10-31 | 2012-05-29 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of venlafaxine hydrochloride |
| US20050176790A1 (en) * | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
| KR20080098691A (ko) * | 2001-09-13 | 2008-11-11 | 깃세이 야쿠힌 고교 가부시키가이샤 | 히드록시노르에페드린 유도체 염산염 |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| ES2291780T3 (es) * | 2004-06-28 | 2008-03-01 | Grunenthal Gmbh | Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol. |
| HRP20170481T1 (hr) * | 2007-12-07 | 2017-05-19 | Grünenthal GmbH | Kristalne modifikacije (1r, 2r)-3-(3-dimentil amino-1-etil-2-metil-propil) fenola |
-
2004
- 2004-06-28 ES ES04015091T patent/ES2291780T3/es not_active Expired - Lifetime
- 2004-06-28 AT AT04015091T patent/ATE368639T1/de active
- 2004-06-28 PL PL04015091T patent/PL1612203T3/pl unknown
- 2004-06-28 EP EP04015091A patent/EP1612203B1/en not_active Expired - Lifetime
- 2004-06-28 PT PT04015091T patent/PT1612203E/pt unknown
- 2004-06-28 DE DE602004007905T patent/DE602004007905T2/de not_active Expired - Lifetime
- 2004-06-28 SI SI200430461T patent/SI1612203T1/sl unknown
- 2004-06-28 DK DK04015091T patent/DK1612203T3/da active
-
2005
- 2005-06-27 AU AU2005256512A patent/AU2005256512B2/en not_active Expired
- 2005-06-27 JP JP2007518520A patent/JP4990764B2/ja not_active Expired - Lifetime
- 2005-06-27 PE PE2005000742A patent/PE20060372A1/es active IP Right Grant
- 2005-06-27 HR HR20110050T patent/HRP20110050T8/xx unknown
- 2005-06-27 DK DK05770026.2T patent/DK1799633T3/da active
- 2005-06-27 BR BR122018014454A patent/BR122018014454B8/pt active IP Right Grant
- 2005-06-27 EP EP05770026A patent/EP1799633B1/en not_active Expired - Lifetime
- 2005-06-27 PT PT05770026T patent/PT1799633E/pt unknown
- 2005-06-27 MX MXPA06014741A patent/MXPA06014741A/es active IP Right Grant
- 2005-06-27 WO PCT/EP2005/006884 patent/WO2006000441A2/en not_active Ceased
- 2005-06-27 CN CN2005800216611A patent/CN1997621B/zh not_active Expired - Fee Related
- 2005-06-27 CA CA2572147A patent/CA2572147C/en not_active Expired - Lifetime
- 2005-06-27 KR KR1020077002099A patent/KR101096501B1/ko not_active Expired - Lifetime
- 2005-06-27 BR BRPI0512792-0A patent/BRPI0512792A/pt not_active Application Discontinuation
- 2005-06-27 NZ NZ551605A patent/NZ551605A/en not_active IP Right Cessation
- 2005-06-27 RU RU2007103297/04A patent/RU2423345C2/ru active
- 2005-06-27 PL PL05770026T patent/PL1799633T3/pl unknown
- 2005-06-27 DE DE602005026031T patent/DE602005026031D1/de not_active Expired - Lifetime
- 2005-06-27 ES ES05770026T patent/ES2359504T3/es not_active Expired - Lifetime
- 2005-06-27 AT AT05770026T patent/ATE496021T1/de active
- 2005-06-27 SI SI200531252T patent/SI1799633T1/sl unknown
- 2005-06-28 AR ARP050102663A patent/AR049949A1/es not_active Application Discontinuation
-
2006
- 2006-12-26 IL IL180373A patent/IL180373A/en active IP Right Grant
- 2006-12-28 US US11/646,232 patent/US20070213405A1/en not_active Abandoned
-
2007
- 2007-01-09 NO NO20070162A patent/NO338605B1/no unknown
- 2007-01-26 ZA ZA200700774A patent/ZA200700774B/xx unknown
- 2007-10-11 CY CY20071101312T patent/CY1106929T1/el unknown
-
2008
- 2008-11-20 US US12/274,747 patent/US20090186947A1/en not_active Abandoned
-
2009
- 2009-12-10 US US12/634,777 patent/US7994364B2/en not_active Expired - Lifetime
-
2011
- 2011-02-16 CY CY20111100192T patent/CY1111530T1/el unknown
- 2011-06-29 US US13/172,009 patent/US20110294898A1/en not_active Abandoned
-
2012
- 2012-08-03 US US13/565,867 patent/US20120302643A1/en not_active Abandoned
-
2013
- 2013-06-21 US US13/923,891 patent/US20140011886A1/en not_active Abandoned
-
2014
- 2014-06-13 US US14/304,313 patent/US20140296346A1/en not_active Abandoned
-
2015
- 2015-11-02 US US14/930,337 patent/US20160122287A1/en not_active Abandoned
-
2016
- 2016-05-30 NO NO20160914A patent/NO341239B1/no unknown
-
2017
- 2017-02-09 US US15/428,613 patent/US20170166515A1/en not_active Abandoned
- 2017-07-04 NO NO20171103A patent/NO343922B1/no unknown
- 2017-07-17 EC ECIEPI201746065A patent/ECSP17046065A/es unknown
- 2017-10-05 US US15/725,967 patent/US20180029976A1/en not_active Abandoned
-
2018
- 2018-04-12 US US15/951,838 patent/US20180230082A1/en not_active Abandoned
- 2018-10-26 US US16/172,100 patent/US20190062263A1/en not_active Abandoned
-
2019
- 2019-09-02 AR ARP190102495A patent/AR116052A2/es not_active Application Discontinuation
- 2019-10-14 US US16/600,884 patent/US20200102261A1/en not_active Abandoned
-
2020
- 2020-06-23 US US16/909,123 patent/US20200385334A1/en not_active Abandoned
-
2021
- 2021-03-08 US US17/194,717 patent/US20210261492A1/en not_active Abandoned
-
2023
- 2023-01-30 US US18/103,410 patent/US20230174458A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116052A2 (es) | Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol | |
| DK1786403T3 (da) | Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
| ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
| CR7583A (es) | Nueva sal formiato de o-desmetil venlafaxina | |
| BRPI0312649A2 (pt) | compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. | |
| DK3219705T3 (da) | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid | |
| NO20171811A1 (no) | Fremgangsmåte for fremstilling av (1R,2R)-3-(3-dimetylamino-1-etyl-2-metyl-propyl)-fenol | |
| NO20053088L (no) | Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon. | |
| CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
| BR9911182B1 (pt) | compostos derivados de biarila com propriedades agonistas de adrenorreceptores beta-3, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto. | |
| ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
| DK1506185T3 (da) | Forbindelser og deres anvendelse som 5-HT-inhibitorer | |
| IL206197A (en) | Crystalline forms of the compound (r1, r2) –3– (3– dimethylamino – 1 – ethyl – 2 – methyl-profile) –phenol processes for their preparation, pharmaceutical compositions containing them, and their use in the preparation of pain treatment compositions | |
| ECSP044973A (es) | Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion | |
| NO20043124L (no) | Aminoindanderivater som serotonin -og norepinefrin-opptaksinhibitorer | |
| UY26731A1 (es) | Combinación de secretagogos de hormona del crecimiento y antidepresivos | |
| BRPI0312413A2 (pt) | compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos | |
| UY28148A1 (es) | Bromhidrato de escitalopram y un metodo para su preparacion | |
| EE200300419A (et) | R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina | |
| NO20074676L (no) | Krystallinske former av (1 RS, 3RS, 6RS)-6-dimetylaminometyl-1-(3-metoksy-fenyl)cykloheksan-1,3-diol hydroklorid | |
| ECSP066938A (es) | Composición farmacéutica que comprende una sal de mirtazapina | |
| BRPI0511819A (pt) | sais de guanilidrazona, composições, processos de fabricação e métodos de uso | |
| AR028324A1 (es) | Nuevos compuestos de heterocicloalquilbenzociclobutano y heteroarilbenzociclobutano, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| EA200970167A1 (ru) | Фармацевтическая композиция, содержащая комбинацию саредутанта и селективного ингибитора обратного захвата серотонина или ингибитора обратного захвата серотонина/норэпинефрина | |
| CL2008003885A1 (es) | Compuestos derivados de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, medicamento que comprende dicho compuesto; y su uso para la contracepcion oral y para el tratamiento de trastornos pre, peri y posmenopausicos. |